Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nal-IRI + oxaliplatin + 5-fluorouracil
- Development stage
- Preclinical
- Lead developer
- Ipsen
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination chemotherapy regimen consisting of liposomal irinotecan (Nal-IRI), oxaliplatin, and 5-fluorouracil. Oxaliplatin forms platinum-DNA adducts that inhibit DNA replication and transcription. 5-Fluorouracil is a pyrimidine analog that disrupts DNA and RNA synthesis. Nal-IRI (liposomal irinotecan) is a topoisomerase I inhibitor in a liposomal formulation.
02
Targets
TOP1 (DNA Topoisomerase I)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on Nal-IRI + oxaliplatin + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nal-IRI + oxaliplatin + 5-fluorouracil.